Create Free Account

By creating account you will get access to hot stocks & personalised emails

Avanos Medical Inc

Healthcare US AVNS

16.31USD
0.13(0.80%)

Last update at 2024-12-19T18:51:00Z

Day Range

16.0716.59
LowHigh

52 Week Range

17.3925.36
LowHigh

Fundamentals

  • Previous Close 16.18
  • Market Cap858.94M
  • Volume197548
  • P/E Ratio39.77
  • Dividend Yield-%
  • EBITDA102.20M
  • Revenue TTM681.50M
  • Revenue Per Share TTM14.79
  • Gross Profit TTM 450.00M
  • Diluted EPS TTM0.47

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 65.20M 5.80M -60.50000M -64.00000M -18.10000M
Minority interest - - - - -
Net income 50.50M 5.20M -27.20000M -45.90000M 57.50M
Selling general administrative 341.90M 300.30M 332.60M 399.10M 340.40M
Selling and marketing expenses - - 332.00M - -
Gross profit 450.00M 364.30M 373.30M 402.20M 390.90M
Reconciled depreciation 47.70M 38.30M 42.90M 36.90M 33.50M
Ebit 74.00M 8.90M -46.10000M -55.70000M 8.30M
Ebitda 122.90M 47.40M -2.00000M -12.10000M 41.80M
Depreciation and amortization 48.90M 38.50M 44.10M 43.60M 33.50M
Non operating income net other 1.20M 0.20M 1.20M 6.70M 7.80M
Operating income 74.00M 8.90M -46.10000M -55.70000M 0.50M
Other operating expenses 746.00M 735.70M 760.90M 753.30M 651.80M
Interest expense 10.00M 3.30M 15.60M 15.00M 26.40M
Tax provision 14.70M 0.60M -33.30000M -18.10000M -9.60000M
Interest income 1.20M 0.20M 1.20M 6.70M 7.80M
Net interest income -8.80000M -3.10000M -14.40000M -8.30000M -18.60000M
Extraordinary items - - - - 69.90M
Non recurring - - - - -
Other items - - - - -
Income tax expense 14.70M 0.60M -33.30000M -18.10000M -9.60000M
Total revenue 820.00M 744.60M 714.80M 697.60M 652.30M
Total operating expenses 376.00M 355.40M 419.40M 457.90M 390.40M
Cost of revenue 370.00M 380.30M 341.50M 295.40M 261.40M
Total other income expense net -8.80000M -3.10000M -14.40000M -8.30000M -18.60000M
Discontinued operations - - - - 66.00M
Net income from continuing ops 50.50M 5.20M -27.20000M -82.10000M -27.70000M
Net income applicable to common shares 50.50M 5.20M -27.20000M -45.90000M 57.50M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1692.40M 1786.90M 1594.60M 1672.80M 1799.60M
Intangible assets 239.50M 251.00M 141.20M 157.70M 184.30M
Earning assets - - - - -
Other current assets 93.30M 13.90M 18.60M 18.90M 23.50M
Total liab 456.10M 495.70M 330.70M 416.30M 534.40M
Total stockholder equity 1236.30M 1291.20M 1263.90M 1256.50M 1265.20M
Deferred long term liab - 25.40M 9.60M 5.70M -
Other current liab 127.40M 98.90M 68.10M 83.20M 114.80M
Common stock 0.50M 0.50M 0.50M 0.50M 0.50M
Capital stock 0.50M 0.50M 0.50M 0.50M 0.50M
Retained earnings -314.90000M -253.10000M -310.30000M -315.50000M -288.30000M
Other liab - 48.90M 18.70M 16.70M 11.20M
Good will 796.10M 819.40M 801.60M 802.50M 800.90M
Other assets - 22.20M 26.50M 71.00M 27.40M
Cash 87.70M 127.70M 118.50M 111.50M 205.30M
Cash and equivalents - - - - -
Total current liabilities 234.60M 185.80M 139.20M 166.30M 212.50M
Current deferred revenue - - - - -
Net debt 121.40M 152.30M 69.00M 137.30M 120.10M
Short term debt 34.20M 19.00M 14.70M 15.50M 14.70M
Short long term debt 8.60M 6.20M - - -
Short long term debt total 209.10M 280.00M 187.50M 248.80M 325.40M
Other stockholder equity 1577.70M 1579.60M 1607.50M 1599.60M 1585.00M
Property plant equipment - 163.90M 168.10M 175.30M 184.50M
Total current assets 487.00M 499.80M 418.60M 467.20M 538.50M
Long term investments - - - - -
Net tangible assets - 220.80M 321.10M 296.30M 280.00M
Short term investments - - - - -
Net receivables 142.80M 167.90M 131.20M 167.90M 163.80M
Long term debt 159.40M 226.30M 130.00M 180.00M 248.10M
Inventory 163.20M 190.30M 150.30M 168.90M 145.90M
Accounts payable 56.30M 67.90M 56.40M 67.60M 83.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -27.00000M -35.80000M -33.80000M -28.10000M -32.00000M
Additional paid in capital - - - - -
Common stock total equity - 0.50M 0.50M 0.50M 0.50M
Preferred stock total equity - - - - -
Retained earnings total equity - -253.10000M -310.30000M -315.50000M -288.30000M
Treasury stock - - -21.30000M -9.80000M -8.90000M
Accumulated amortization - - - - -
Non currrent assets other 19.30M 17.60M 16.50M 11.80M 11.30M
Deferred long term asset charges - - - - -
Non current assets total 1205.40M 1287.10M 1176.00M 1205.60M 1261.10M
Capital lease obligations 41.10M 47.50M 57.50M 68.80M 77.30M
Long term debt total - 226.30M 130.00M 180.00M 248.10M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -135.40000M -21.00000M -4.00000M -108.10000M 639.50M
Change to liabilities 28.30M 21.50M -93.20000M -68.30000M -130.60000M
Total cashflows from investing activities -135.40000M -21.00000M -24.20000M -108.10000M 639.50M
Net borrowings 100.50M -50.00000M -69.80000M -0.20000M -340.60000M
Total cash from financing activities 56.70M -55.30000M -70.00000M 1.50M -324.40000M
Change to operating activities -4.10000M 26.00M -67.80000M 46.10M -112.30000M
Net income 50.50M 5.20M -27.20000M -45.90000M 57.50M
Change in cash 9.20M 7.00M -93.80000M -179.20000M 164.80M
Begin period cash flow 118.50M 111.50M 205.30M 384.50M 219.70M
End period cash flow 127.70M 118.50M 111.50M 205.30M 384.50M
Total cash from operating activities 90.90M 87.30M -2.50000M -74.50000M -145.60000M
Issuance of capital stock - - - - -
Depreciation 47.70M 38.30M 42.90M 36.90M 33.50M
Other cashflows from investing activities -116.10000M - - -57.50000M 65.70M
Dividends paid - - - - -
Change to inventory -30.90000M 17.20M -21.80000M -21.30000M -34.50000M
Change to account receivables -24.70000M -10.80000M 45.80M -0.80000M 67.40M
Sale purchase of stock -45.50000M -11.50000M -0.90000M -3.60000M -0.90000M
Other cashflows from financing activities 398.80M 26.20M 185.70M 5.30M 15.50M
Change to netincome 17.00M 21.20M 35.80M 11.10M -86.40000M
Capital expenditures 19.30M 21.00M 20.20M 50.60M 49.10M
Change receivables -24.70000M -10.80000M 45.80M -0.80000M 67.40M
Cash flows other operating 3.00M -5.30000M 15.20M 13.80M -52.50000M
Exchange rate changes - - - - -4.70000M
Cash and cash equivalents changes 12.20M 11.00M -96.70000M -181.10000M 164.80M
Change in working capital -24.30000M 26.00M -67.80000M -59.60000M -143.40000M
Stock based compensation 15.90M 13.20M 12.10M 10.50M 10.50M
Other non cash items 1.10M 8.00M 11.60M -9.90000M -107.40000M
Free cash flow 71.60M 66.30M -22.70000M -125.10000M -194.70000M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVNS
Avanos Medical Inc		 0.13 0.80% 16.31 39.77 - 1.26 0.69 1.42 11.40
ABT
Abbott Laboratories		 1.29 1.15% 113.22 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -0.41 0.11% 358.76 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 0.41 0.51% 80.44 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 1.08 1.23% 89.11 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Avanos Medical Inc

5405 Windward Parkway, Alpharetta, GA, United States, 30004

Key Executives

Name Title Year Born
Mr. Joseph F. Woody CEO & Director 1966
Mr. Michael C. Greiner Sr. VP, CFO & Principal Accounting Officer 1973
Mr. David Edward Ball Sr. VP of Global Supply Chain & Procurement 1959
Mr. William David Haydon Sr. VP & GM of Pain Management 1967
Mr. Kerr W. Holbrook Sr. VP & GM of Chronic Care 1967
Mr. David Crawford VP of FP&A and Investor Relations and Treasurer NA
Ms. Michelle Scharfenberg Sr. VP and Chief Ethics & Compliance Officer NA
Ms. Mojirade James Sr. VP, Gen. Counsel & Corp. Sec. 1967
Mr. Scott Galovan VP of Strategy & Corp. Devel. NA
Mr. Arjun Ranjan Sarker Sr. VP of International 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.